In one paragraphArticle in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
28 authors.
Sophie Li *Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3099-9906 Chia-Chin Wu *Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5208-6016 Vicente R MarczykDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7005-722X Matthew A LobergDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0001-5840-4591 Aatish ThennavanDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-7534-5359 Maxime TarabichiInstitute for Interdisciplinary Research (IRIBHM) - Jacques E. Dumont, Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0002-1635-2348 Li XuDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6097-0979 Ying C HendersonDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1762-1765 Meghan E MartinDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0004-0911-6381 Tuan M TranDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0008-9362-8150 Dzifa Y DuoseDepartment of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6763-9736 Alexander Sanchez-EspitiaDepartment of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4074-6099 Rajyalakshmi LuthraDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-7133-0221 Quanhu ShengDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0001-8951-9295 George J XuDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0003-2129-5701 Eric C HuangDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington.ORCID 0000-0002-8745-0025 Marie-Claude HofmannDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4899-8039 Xiao ZhaoDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2485-9445 Stephen Y LaiDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8301-7286 S Mohsen HosseiniDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3626-9928 Michelle D WilliamsDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9133-7332 Wenyi WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0617-9438 Sarah HamidiDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1528-9885 Mark E ZafereoDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7918-9739 Maria E CabanillasDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5124-1811 Nicholas E NavinDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2106-8624 Vivian L WeissDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0003-0874-3207 Jennifer R WangDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0807-3832 Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3MVanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MThe Role of Cancer-Associated Fibroblasts in Thyroid CarcinomaR01CA272875 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WEISS, VIVIAN LEE · 2022 to 2025
$2.5MThe role of Wnt signaling in aggressive thyroid carcinomaK08CA240901 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WEISS, VIVIAN LEE · 2020 to 2024
$1.1MCancer-associated fibroblasts promote thyroid cancer malignancy through Wnt signalingF30CA281125 · NCI · VANDERBILT UNIVERSITY · PI LOBERG, MATTHEW A · 2023 to 2025
$141kAmerican Cancer Society (ACS) 133934-CSDG-19-216-01-TBGAmerican Cancer Society (ACS) RSG-22-084-01-MMAmerican Society of Cytopathology Foundation (ASCF) Young Investigator AwardAmerican Thyroid Association (ATA) 2019-0000000090National Institutes of Health (NIH) F30CA281125National Institutes of Health (NIH) K08CA240901National Institutes of Health (NIH) R01CA272875National Institutes of Health (NIH) VCORCDP K12CA090625NCI NIH HHS F30 CA281125NCI NIH HHS K08 CA240901NCI NIH HHS K12 CA090625NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA272875University of Texas MD Anderson Cancer Center (MD Anderson) Petrick Thyroid Cancer Research Fund
6 · The paper itselfAbstract
purposePapillary thyroid carcinoma (PTC) exhibits heterogeneous behavior, underscoring the need for effective biomarkers and improved risk stratification methods. We developed a thyrocyte-derived gene signature, Prognostic RNA Expression Cell-specific Integrated Signature (PRECISE), using single-cell RNA sequencing (scRNA-seq) and single-nucleus RNA sequencing (snRNA-seq) and evaluated its prognostic utility across cohorts. EXPERIMENTAL
designPRECISE was developed using a discovery cohort of patients with PTC [MD Anderson Cancer Center (MDACC), n = 109, median follow-up = 14 years]. Within the cohort, 11 PTC tumors and 4 normal thyroid samples were successfully sequenced using snRNA-seq. Differentially expressed genes were integrated with previously identified thyrocyte-associated genes from scRNA-seq. Prognostic significance was assessed using bulk RNA-seq in the discovery cohort and validated in two additional cohorts [Vanderbilt University Medical Center (VUMC), n = 65; The Cancer Genome Atlas (TCGA), n = 370]. A rank-based single-sample method was used for score calculation. Associations between PRECISE and progression-free survival (PFS) and disease-specific survival (DSS) were evaluated using multivariate Cox models, and predictive models were compared using Harrell's C-statistic and likelihood ratio tests.
resultsPRECISE is comprised of 41 epithelial genes downregulated in PTC tumor cells. Higher PRECISE was significantly associated with shorter PFS across all three cohorts [MDACC: hazard ratio (HR) = 1.64, P = 0.002; VUMC: HR = 2.54, P < 0.001; TCGA: HR = 1.63, P = 0.012] and remained significant after tumor-node-metastasis stage adjustment in two cohorts with ≥5 years of follow-up [MDACC adjusted HR (aHR) = 1.42, P = 0.038; VUMC aHR = 2.12, P = 0.024]. PRECISE was also associated with DSS in these cohorts (MDACC: HR = 4.16, P < 0.001; VUMC: HR = 2.23, P = 0.010). Incorporating PRECISE significantly improved predictive performance for PFS and DSS beyond stage-based models.
conclusionsPRECISE is a thyroid epithelial gene signature with independent prognostic value in PTC.
Indexed as
Biomarkers, TumorThyroid Cancer, PapillaryThyroid NeoplasmsTranscriptomeAdultAgedFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisSingle-Cell Gene Expression AnalysisThyroid GlandBiomarkers, Tumor
Identifiers
PMID42008746
PMCPMC13264843
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390